Patents by Inventor Patrick Hoffmann
Patrick Hoffmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9150664Abstract: The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.Type: GrantFiled: November 15, 2012Date of Patent: October 6, 2015Assignees: AMGEN RESEARCH (MUNICH) GMBH, BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Peter Kufer, Tobias Raum, Patrick Hoffmann, Roman Kischel, Ralf Lutterbuese, Doris Rau, Paul Adam, Eric Borges, Barbara Hebeis, Susanne Hipp
-
Publication number: 20150037334Abstract: The present invention relates to a binding molecule comprising at least three domains comprised in at least one polypeptide chain, wherein the first binding domain is a binding domain which is capable of binding to a cell surface molecule on a target cell, the second binding domain is a binding domain which is capable of binding to the T cell CD3 receptor complex, and the third domain is a binding domain which is capable of binding to serum albumin, wherein said third domain is positioned at the C-terminus of said second domain. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.Type: ApplicationFiled: March 1, 2013Publication date: February 5, 2015Inventors: Peter Kufer, Tobias Raum, Ralf Lutterbuese, Patrick Hoffmann, Markus Muenz, Johannes Brozy, Majk Kvesic
-
Publication number: 20150023967Abstract: The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster3 of BCMA, and the second binding domain is capable of binding to the Tcell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.Type: ApplicationFiled: November 15, 2012Publication date: January 22, 2015Inventors: Peter Kufer, Tobias Raum, Patrick Hoffmann, Roman Kischel, Ralf Lutterbuese, Doris Rau, Paul Adam, Eric Borges, Barbara Hebeis, Susanne Hipp
-
Publication number: 20140348837Abstract: The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.Type: ApplicationFiled: November 15, 2012Publication date: November 27, 2014Applicants: Amegen Research (Munich) GmbH, Boehringer Ingellheim iInternational GmbhInventors: Peter Kufer, Tobias Raum, Patrick Hoffmann, Roman Kischel, Ralf Lutterbuese, Doris Rau, Paul Adam, Eric Borges, Barbara Hebeis, Susanne Hipp
-
Publication number: 20140322218Abstract: The present invention provides to a antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention relates to a nucleic acid sequence encoding the antibody construct, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention relates a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: ApplicationFiled: January 27, 2014Publication date: October 30, 2014Applicant: AMGEN RESEARCH (MUNICH) GMBHInventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, Shawn Jeffries, Chadwick T. King, Brian Mingtung Chan, Peter Kufer, Ralf Lutterbüse, Tobias Raum, Patrick Hoffmann, Doris Rau, Roman Kischel, Bryan Lemon, Holger Wesche
-
Publication number: 20140228316Abstract: The present invention relates to a PPS for use in the amelioration, treatment or prophylaxis of neurological adverse events caused by a CD3 binding domain. Kits comprising a PPS, a CD3 binding domain and instructions for use which indicate that the PPS is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.Type: ApplicationFiled: February 8, 2014Publication date: August 14, 2014Applicant: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
-
Publication number: 20140227272Abstract: The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.Type: ApplicationFiled: February 8, 2014Publication date: August 14, 2014Applicant: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
-
Patent number: 8518403Abstract: A composite polypeptide, said composite polypeptide comprising a desired polypeptide and an expression enhancing domain (“EED”), said EED comprising first and second cysteine amino acid residues Cys1 and Cys2, respectively, Cys1 being located closer to the N-terminus of the composite polypeptide molecule than Cys2, wherein Cys1 and Cys2 are separated by a polypeptide linker, said linker—being free of cysteine and proline;—defining a length sufficient to allow Cys1 and Cys2 to engage in an intramolecular disulfide bond with one another; and—having a flexible polypeptide conformation essentially free of secondary polypeptide structure in aqueous solution, wherein at least one of Cys1 and Cys2 is derivatized with a derivatization moiety.Type: GrantFiled: July 15, 2005Date of Patent: August 27, 2013Assignee: Amgen Research (Munich) GmbHInventors: Patrick Hoffmann, Silke Mittelstrass, Jens Hennecke, Tobias Raum
-
Publication number: 20130129730Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.Type: ApplicationFiled: April 1, 2011Publication date: May 23, 2013Inventors: Peter Kufer, Ralf Lutterbuese, Matthias Klinger, Petra Fluhr, Doris Rau, Susanne Hausmann, Carole Steiger, Tobias Raum, Patrick Hoffmann, Roman Kischel, Evelyne Schaller, Susanne Mangold
-
Publication number: 20120244162Abstract: The present invention relates to a polypeptide comprising a first human binding domain capbable of binding to an epitope of human and non-chimpanzee CD3? (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acid sequences encoding the polypeptide, to vectors comprising the nucleic acid sequences and to host cells comprising the nucleic acid sequences or vectors containing the nucleic acid sequences. In another aspect, the invention provides for a pharmaceutical composition comprising the polypeptide and methods of medical treatment or use of the polypeptide.Type: ApplicationFiled: February 29, 2012Publication date: September 27, 2012Inventors: Peter KUFER, Tobias Raum, Roman Kischel, Ralf Lutterbüse, Patrick Hoffmann, Matthias Klinger, Doris Rau, Susanne Mangold
-
Publication number: 20120034228Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an antigen selected from the group consisting of Prostate Stem Cell Antigen (PSCA), B-Lymphocyte antigen CD19 (CD19), hepatocyte growth factor receptor (C-MET), Endosialin, the EGF-like domain 1 of EpCAM, encoded by exon 2, Fibroblast activation protein alpha (FAP alpha) and Insulin-like growth factor I receptor (IGF-IR or IGF-1R). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production.Type: ApplicationFiled: October 1, 2009Publication date: February 9, 2012Inventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbüse, Patrick Hoffmann, Doris Rau, Matthias Klinger, Susanne Mangold, Claudia Blümel
-
Publication number: 20110293619Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain anti-body molecule.Type: ApplicationFiled: October 1, 2009Publication date: December 1, 2011Inventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lütterbuse, Patrick Hoffmann, Doris Rau, Susanne Mangold, Matthias Klinger, Evelyne aschaller, Susanne Hausmann, Petra Fluhr, Carola Steiger
-
Publication number: 20100183615Abstract: The present invention relates to a polypeptide comprising a first human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.Type: ApplicationFiled: April 3, 2008Publication date: July 22, 2010Applicant: MICROMET AGInventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbuese, Patrick Hoffmann, Matthias Klinger, Doris Rau, Susanne Mangold
-
Publication number: 20100150918Abstract: The present invention relates to a polypeptide comprising a human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. In a further aspect the invention provides a method for the identification of polypeptides comprising a cross-species specific binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3? (CD3 epsilon).Type: ApplicationFiled: April 3, 2008Publication date: June 17, 2010Applicant: MICROMET AGInventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbuese, Patrick Hoffmann, Matthias Klinger, Doris Rau, Susanne Mangold
-
Publication number: 20090053223Abstract: A composite polypeptide, said composite polypeptide comprising a desired polypeptide and an expression enhancing domain (“EED”), said EED comprising first and second cysteine amino acid residues Cys1 and Cys2, respectively, Cys1 being located closer to the N-terminus of the composite polypeptide molecule than Cys2, wherein Cys1 and Cys2 are separated by a polypeptide linker, said linker—being free of cysteine and proline;—defining a length sufficient to allow Cys1 and Cys2 to engage in an intramolecular disulfide bond with one another; and—having a flexible polypeptide conformation essentially free of secondary polypeptide structure in aqueous solution, wherein at least one of Cys1 and Cys2 is derivatized with a derivatization moiety.Type: ApplicationFiled: July 15, 2005Publication date: February 26, 2009Inventors: Patrick Hoffmann, Silke Mittelstrass, Jens Hennecke, Tobias Saum
-
Publication number: 20080312411Abstract: The invention relates to a use of an activated polymer to separate a non-covalently associated polypeptide multimer comprising multiple polypeptide subunits into multiple polypeptide subunits.Type: ApplicationFiled: February 15, 2006Publication date: December 18, 2008Inventors: Andreas Wolf, Patrick Hoffmann, Julia Hepp Nee Henckel, Tobias Raum
-
Patent number: 7426281Abstract: The invention relates to an acoustic transducer generating a sound radiation by compression and expansion of an air mass situated between a mobile membrane and a fixed surface or between two mobile membranes. The present invention concerns a transducer or acoustic loudspeaker of electrodynamic type designed to emit sound waves from a modulated electrical signal. The particular arrangement of the constituent elements of the transducer as presented in the invention enables the generation of an acoustic radiation by compression and expansion of the air mass located between a mobile membrane and a fixed surface or anvil which are distinguished by being placed opposite one another. The direction of the resulting acoustical wave is perpendicular to the direction of displacement of the membrane. This manner of generating an acoustic wave enables the production of transducers with specific electroacoustic directivity characteristics.Type: GrantFiled: February 6, 2004Date of Patent: September 16, 2008Assignee: Rötelzeichnung Holding A.G.Inventor: Patrick Hoffmann
-
Publication number: 20060147076Abstract: The invention relates to an acoustic transducer generating a sound radiation by compression and expansion of an air mass situated between a mobile membrane and a fixed surface or between two mobile membranes. The present invention concerns a transducer or acoustic loudspeaker of electrodynamic type designed to emit sound waves from a modulated electrical signal. The particular arrangement of the constituent elements of the transducer as presented in the invention enables the generation of an acoustic radiation by compression and expansion of the air mass located between a mobile membrane and a fixed surface or anvil which are distinguished by being placed opposite one another. The direction of the resulting acoustical wave is perpendicular to the direction of displacement of the membrane. This manner of generating an acoustic wave enables the production of transducers with specific electroacoustic directivity characteristics.Type: ApplicationFiled: February 6, 2004Publication date: July 6, 2006Inventor: Patrick Hoffmann